Latest Pharmaceuticals News

Page 6 of 89
Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.
Ada Torres
Ada Torres
21 Oct 2026
Recce Pharmaceuticals says a review of blinded Phase 3 data for its RECCE 327 Gel showed strong efficacy and a positive safety profile. An independent committee is expected to assess unblinded data from 75 patients as soon as mid-November, while recruitment continues.
Ada Torres
Ada Torres
20 Oct 2026
Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.
Victor Sage
Victor Sage
19 Oct 2026
Algorae has secured exclusive Australian commercial rights across eight Umedica-branded molecules while separately advancing a Umedica-supplied product towards regulatory approval. The broader arrangement remains partly non-binding, with financial terms undisclosed and TGA approval still pending.
Victor Sage
Victor Sage
19 Oct 2026
Amplia Therapeutics has told ASX it is unaware of any undisclosed information that explains a sharp fall in its share price and a surge in trading volume. The response followed an ASX price query issued after the stock dropped from $0.100 to $0.079 on 16 October.
Victor Sage
Victor Sage
16 Oct 2026
Mesoblast has reported a sharp first-quarter commercial improvement, with Ryoncil revenue rising 44% and net operating cash spend falling 85% year on year. The company ended September with US$99 million in cash, although the figures remain preliminary.
Victor Sage
Victor Sage
16 Oct 2026
Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.
Victor Sage
Victor Sage
16 Oct 2026
BLS Pharmaceuticals has opened FY27 with record quarterly revenue, positive operating cash flow and reaffirmed full-year guidance. The report contains conflicting Q1 revenue figures of $26.7 million and $27.5 million, while its Scotland expansion remains subject to regulatory approval.
Victor Sage
Victor Sage
15 Oct 2026
Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.
Victor Sage
Victor Sage
14 Oct 2026
Clever Culture Systems has appointed PSC Biotech as its sole sales agent for APAS Independence across pharmaceutical manufacturing markets in the US, Canada and Singapore. The agreement expands CCS’s reach beyond its direct focus on major global drugmakers, but any material revenue uplift is not expected before FY28.
Victor Sage
Victor Sage
14 Oct 2026
Firebrick Pharma has raised approximately $732,000 from strategic investors, with its Philippines licensing partner investing $631,750 to lift its holding above 10%. The funding will support US retail production, a Singapore product launch and working capital.
Ada Torres
Ada Torres
12 Oct 2026
Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.
Ada Torres
Ada Torres
9 Oct 2026

Browse the archive

Full archive